MELBOURNE, Australia — November 24, 2025 — Leads & Copy — Gelteq Limited, a clinical and science-based company specializing in gel-based oral delivery solutions, has announced positive preclinical results indicating that its proprietary gel formulation significantly improves bioavailability compared to a leading on-market reference antihistamine product.
In a comparative pharmacokinetic study, Gelteq’s formulation showed a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax). The study results demonstrate that Gelteq’s gel-based delivery technology can significantly enhance the oral bioavailability of drugs and provide broad benefits in solving drug delivery, swallowing, and patient compliance issues.
Nathan Givoni, CEO of Gelteq, stated that these results represent a major technical and commercial milestone for the company. He emphasized that the 38–45% improvement in bioavailability is transformative and validates the platform’s ability to meaningfully enhance the performance of established drugs. Givoni also noted that these results position Gelteq to pursue a broader portfolio of pharmaceutical opportunities where similar outcomes can be achieved via its proprietary gel-based delivery technology.
The findings extend beyond the specific antihistamine evaluated in the study, because the test compound is water-soluble, the demonstrated bioavailability improvement provides a strong foundation for applying Gelteq’s platform across a range of other water-soluble drug classes, significantly broadening the Company’s commercial scope.
Mr. Givoni added that these results support their strategy of partnering and developing gel-based formulations across a wide range of therapeutically relevant compounds and that they believe this opens up opportunities well beyond the antihistamine market, and into much larger drug categories where improved absorption, ease of administration, and patient-friendly formats can create immediate value.
The Company anticipates using these results to further pursue an FDA approval pathway for an antihistamine product and to increase engagement with potential pharmaceutical partners interested in next-generation drug delivery formats.
Gelteq Ltd. is headquartered in Melbourne, Australia. It is a clinical and science-based company dedicated to developing and commercializing gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing.
Matt Kreps, Investor Relations
Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Source: Gelteq Ltd.
